Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
-
Zhonghua Gan Zang Bing Za Zhi · Mar 2017
Review[Research advances in nonalcoholic fatty liver disease and alcoholic liver disease in 2016].
Nonalcoholic fatty liver disease (NAFLD) has become the most important liver disease in the world and its prevalence rate still tends to increase. However, there are still no effective drugs so far. The complex and dynamic interactions between multiple effects/mediators in the pathophysiology of NAFLD provide new insights and help with stratification and redefinition of clinical phenotypes and evaluation of disease susceptibility and multiplicity of progression. ⋯ Alcoholic liver disease is a great harm to health and an important cause of end-stage liver disease. Some progress has been made in the research on alcoholic liver disease around the world in 2016. This article reviews the research advances in alcoholic liver disease in 2016 from the aspects of epidemiology, pathogenesis, diagnostic and therapeutic methods, and prognosis.
-
Zhonghua Gan Zang Bing Za Zhi · Mar 2017
[Clinical timing and benefit of antiviral treatment for hepatitis C].
Current treatments for hepatitis C include pegylated interferon-α (Peg-IFNα) and ribavirin (RBV) combination therapy and direct antiviral agents (DAAs). Antiviral treatment can be initiated after 4 to 6 months of clinical observations for patients with acute infections, but should be started as early as possible for those with chronic infections. ⋯ It has been reported that there are numerous clinical benefits of antiviral treatment for hepatitis C. However, the long-term impact of DAAs treatment including efficacy and safety is limited and remains to be explored.
-
Zhonghua Gan Zang Bing Za Zhi · Mar 2017
[Opportunities and challenges for the treatment of chronic hepatitis C].
Chronic hepatitis C is a great threat to human health. The World Health Organization presented Draft global health sector strategies in 2016, the goal of the draft strategy is to eliminate viral hepatitis as a public health threat by 2030, and to contribute to the achievement of universal health coverage.